Designer molecules that can speci®cally target pre-determined DNA sequences provide a means to modulate endogenous gene function. Different classes of sequence-speci®c DNA-binding agents have been developed, including triplex-forming molecules, synthetic polyamides and designer zinc ®nger proteins. These different types of designer molecules with their different principles of engineered sequence speci®city are reviewed in this paper. Furthermore, we explore and discuss the potential of these molecules as therapeutic modulators of endogenous gene function, focusing on modulation by stable gene modi®cation and by regulation of gene transcription.
INTRODUCTION
Knowledge of the biochemical and genetic abnormalities underlying disease allows for the rational design and development of therapies and therapeutic agents. A promising rational drug design approach is the development of agents that are designed to speci®cally modulate endogenous gene function through sequence-speci®c interaction with DNA. These designer molecules would be invaluable therapeutic tools in those cases where the molecular bases of a given disease would rationally warrant the activation or inhibition of a particular gene, or a set of genes.
DNA-sequence-speci®c modulation of endogenous gene function, as compared with conventional gene therapy approaches, is an attractive concept. In comparison with strategies that target downstream gene products (mRNA or protein), modulation of endogenous gene function (at the DNA level), be it permanent or transient, is potentially more effective because theoretically fewer`copies' would have to be targeted. Also with respect to`gene augmentation' strategies, the concept of endogenous gene modulation has appealing qualities. First, correction or up-regulation of a mutated or under-expressed endogenous gene ensures the correct stoichiomieric expression of the different splice variants of that gene, whereas an introduced gene usually concerns only a single cDNA variant. Furthermore, corrective endogenous gene targeting, unlike approaches introducing integrating gene copies, is not anticipated to suffer from loss of function due to methylation.
Several distinct mechanisms exist through which sequencespeci®c binding of duplex DNA can be achieved and on which strategies to make agents with designed DNA-sequence speci®cities have been based. First of all, there is the phenomenon of triple helix formation. Single-stranded oligonucleotides have been found to be able to bind duplex DNA in the major groove in a sequence-speci®c manner, thereby forming a triple helical structure. Secondly, there is the mechanism of certain synthetic polyamides that have been engineered by rational design to bindÐwith sequence speci®cityÐin the minor groove of duplex DNA. Finally, there are different mechanisms by which natural DNA binding proteins are capable of binding duplex DNA in a sequence-speci®c manner. Several attempts have been described to exploit the DNA binding capacity of these proteins. One particular type of DNA binding protein, the Cys 2 His 2 zinc ®nger type of protein, has proven to be particularly well-suited as a framework for the development of designer molecules with new sequence speci®cities.
First, this literature study will review the advances made in the development of agents with engineered DNA-sequence speci®cities, covering the modalities of triplex-forming oligonucleotides (TFOs), synthetic polyamides and Cys 2 His 2 zinc ®nger proteins. Next, it explores the application of these different agents as modulators of endogenous gene function, focusing on stable gene modi®cation and on regulation of gene transcription.
TRIPLEX-FORMING MOLECULES
One approach for tailoring molecules that speci®cally recognize pre-determined sequences has been based on triple helix formation. The phenomenon of triple helix formation is the binding of a third polynucleotide strand to a duplex nucleic acid, thereby forming a triple-helical structure ( Fig. 1) (1). It was found that the third nucleotide strand binds in the major groove of the duplex, to one of the two Watson±Crick strands *To whom correspondence should be addressed. Tel: +31 50 363 7866; Fax: +31 50 363 7953; Email: m.g.rots@farm.rug.nl in a sequence-speci®c manner (2±4). This property of sequence speci®city has based the potential of triplex-based applications that aim to target a single-strand DNA (TFO) to a speci®c target site in duplex DNA.
Research on exploiting the sequence speci®city of TFO binding, much of which has been reviewed recently by Faria et al. (5, 6 ), Knauert and Glazer (7) and Vasquez and Glazer (8) , showed that there are some general principles on how TFOs recognize DNA sequences. It has been established that TFOs bind along the major groove of a duplex DNA target site, to a purine-rich target site strand. Respective to this target strand, TFOs can bind either in a parallel or an anti-parallel fashion (as explained below). The nucleotide bases of the target strand are speci®cally recognized by TFO bases through consecutive hydrogen interactions. Essentially, each base of the TFO binds to one target strand base, thereby formingÐas the targeted base is already half of a Watson±Crick base pairÐ a base triplet. The possible`base-pairing' combinations that were found to exist between the bases in the TFO and the bases in the purine-rich target strand have given rise to generalized recognition codes for binding of TFOs to DNA (Fig. 2) .
The DNA-recognition codes are different for the parallel and the anti-parallel fashion of TFO binding. When a TFO binds in parallel respective to the purine-rich target strand, it does so according to the so-called pyrimidine motif ( Fig. 2 ) (4, 9, 10) . In this motif the adenine and guanine residues of the purine-rich target strand are, respectively, recognizedÐ through Hoogsteen hydrogen bondsÐby thymine and cytosines (hence`pyrimidine motif') of the TFO. A requirement for triplex formation by pyrimidine motif TFOs is that the nitrogen atom at position 3 on the cytosine residue is protonated (11) . At physiological pH levels this is not the case and, therefore, this requirement constitutes a limitation for parallel binding by unmodi®ed TFOs in cellular contexts. In case of the anti-parallel fashion of binding, the TFO binds to the target strand according to the so-called purine motif (Fig. 2 ) (4, 9, 12) . Here the adenines and guanines of the purine-rich target strand are, respectively, recognizedÐthrough Reverse Hoogsteen bondsÐby adenines and guanines (hence`purine motif') of the TFO.
The general principles for TFO DNA recognition as described above indicate that TFOs can recognize purine-rich target strands of duplex DNA and that they do so according to speci®c TFO base±target strand base interactions. Due to these characteristics, TFOs are potentially applicable as designer molecules that speci®cally recognize pre-determined endogenous DNA sequences. However, a major limitation to this application is that TFOs can only bind to purine-rich target strands. This limits the choice of endogenous gene target sites to polypurine-polypyrimidine stretches in duplex DNA. It would be advantageous if, besides the purine bases, the pyrimidine bases could also be speci®c-ally recognized by TFOs, as this would enable TFOs to be targeted to any desired genomic site.
As already mentioned, TFOs bind target sites that are rich in purines, implying that at least some pyrimidine bases in the purine-rich target site are apparently tolerated. Different studies have demonstrated that this is the case when thosè inversion' sites in the purine-rich target strand are met by certain bases in the TFO molecule (13±15). These matching bases in the TFO are different for the parallel and the antiparallel fashion of binding. However, although these tolerations of pyrimidines among a majority of purines provide slightly more¯exibility in target site choice, target strandsÐ for TFOs consisting of natural nucleotide basesÐare still required to consist mostly of purines.
As outlined above, the requirement for a polypurinepolypyrimidine target stretch for triplex formation is a great limitation to the application of TFOs. Apart from this, however, there have been more limitations to the use of TFOs. These have concerned binding af®nity and speci®city, uptake into cells and tissues, and in vivo stability. Major research efforts have been devoted to addressing these limitations by improving TFO characteristics through chemical modi®cations. Of course only those applications where TFOs are administered as chemical drugs can bene®t from these improving modi®cations; any gene therapeutic application where TFOs are transferred to cells as genetic information to be expressed in situ cannot make use of such improvements. The many chemical TFO modi®cations have involved modi®cations to the phosphodiester backbone (16±19), the ribose (20±24) and the base moiety (25±27), as outlined below.
Modi®cations to the TFO backbone have often been made in attempts to increase the general af®nity of the TFO for (16, 18, 19, 28) . This has been done by making neutral or positive backbones, thereby eliminating the electrostatic repulsion between the TFO and the duplex. Backbone modi®cations often involved the replacement of certain of its residues, such as the non-bridging (negatively charged) oxygen on the phosphodiester phosphate (18, 19) . However, in case of peptide nucleic acids (PNAs)Ðwhich are molecules that can form very stable triplexesÐthe whole phosphodiester backbone is replaced by an uncharged polyamide backbone (29±31). Modi®cations made to the ribose moiety in oligonucleotides have also been able to generate derivatives with advantageous properties (20±24). These modi®cations were mostly made at the 2¢ position of ribose and have led to TFO derivatives that were nucleaseresistant, formed more stable triplexes, or were chemically more stable. Modi®cations made to nucleotide basesÐmainly at carbon positions 4 and 5 of pyrimidine bases, and at carbon position 8 of purine bases (8)Ðhave also led to some improvements to TFOs (25±27). As already mentioned, an important limitation of TFOs of the pyrimidine motif is that protonation of the nitrogen at position 3 of cytosineÐwhich does not occur at physiological pH levelsÐis required for triplex formation (Fig. 2) . In order to address this problem, several studies have worked on the derivation of cytosine analogs that allow for pH-independent triplex formation (25±27). Furthermore, base modi®cations have also been made in attempts to expand the triplex-binding code to recognize all four natural bases instead of only the purines, thereby addressing one of the major problems of TFO applicability. As mentioned above, inversion sites (i.e. sites where a pyrimidine disrupts a homopurine stretch) are tolerated to some extent when matched by certain bases. Various chemical base analogs were shown to have higher af®nity at the different inversion sites than these natural bases had (32±34). Thus, the use of TFOs with chemically modi®ed bases has potential to overcome, at least in part, the requirement of polypurine-polypyrimidine target sites.
SYNTHETIC POLYAMIDES
By exploiting the DNA-binding mechanisms of the natural products netropsin and distamycin, different groups, among which those of Dervan, Denny, Goodsell and Lown, have attempted to rationally design a mechanism of sequencespeci®c minor groove DNA recognition, according to a universal code, by small synthetic polyamides (35±40). Based on these efforts, a certain class of synthetic polyamides has been generated that serves well as a framework for engineered sequence speci®city (Fig. 3) (35,38,41±43 ). These polyamides can bind in the minor groove of DNA through speci®c recognition of the four Watson±Crick base pairs by cognate pairs of certain amino acids, namely hydroxypyrrole (Hp), imidazole (Im) and pyrrole (Py). The principle for this polyamide mechanism of DNA recognition is a structure containing two side-by-side anti-parallel polyamide stretches. This structureÐwhich is mostly a hairpinÐallows for sideby-side amino acid pairings to be formed. In the minor groove of DNA, each of the four Watson±Crick base pairs is speci®cally bound, through hydrogen bonds, by one of these side-by-side pairs of Hp, Im and Py amino acids. Speci®cally, the polyamide amino acid pairs Py/Im, Py/Hp, Hp/Py and Im/Py respectively recognize the C±G, A±T, T±A and G±C base pairs. This framework of sequence-speci®c DNA-binding by synthetic polyamides is exempli®ed by Figure 4A .
Being relatively small molecules, the synthetic polyamides described above are interesting candidates for DNA-sequencespeci®c modulators of gene expression. However, a shortcoming of the ®rst generation of these molecules is the relative shortness of their DNA target sites. These target sites cannot be extended simply by increasing the number of contiguous amino acid pairings in the polyamide molecule, as this is thought to lead to over-bending of the polyamide structure relative to the minor groove of DNA (44) . In this regard, the upper structural limit of polyamide length was found to be ®ve amino acid pairings, which can recognize a DNA target site of up to ®ve W-C base pairs.
To extend the DNA binding sites of polyamides beyond ®ve base pairs, several approaches have been explored (38, 42) . Among these has been the extension of hairpin polyamides by insertion of b-alanine pairs that relax the curvature of the polyamide ligand (Fig. 4B) (43) . Another approach for targeting longer DNA sitesÐof up to 10 or 11 bpÐis the generation of covalent dimers of hairpin polyamides. For instance, tandem polyamide hairpins have been made by connecting two hairpins turn-to-tail ( Fig. 4B) (44) . In this regard, a recent study found several general motifs that can be used to link any two hairpins in the turn-to-tail manner (44) . Another recent study also made covalent dimers of polyamide hairpins, but in this case they were connected turn-to-turn ( Fig. 4B) (45) .
DESIGNER ZINC FINGER PROTEINS
The structural principles of sequence-speci®c DNA recognition by DNA-binding proteins, especially certain types of transcription factors (TFs), could provide frameworks for the design of tailor-made, site-speci®c DNA binding proteins. In general, natural TFs have a modular structure with at least two functional domains: a DNA-binding domain (DBD) and a trans-effecting domain. In addition, some TFs contain dimerization domains, and a few, small molecule regulated TFs, harbor ligand-binding domains. The DBDs of most TFs bind to DNA through a structural motif that presents an a-helix to the major groove of DNA. There are four major types of these motifs, namely the helix±turn±helix motif, the zinc ®nger motif, the leucine zipper motif and the helix±loop± helix motif. As a framework for the design of new DNA binding proteins, the Cys 2 His 2 (or class I) zinc ®nger motif, the most common DNA-binding motif in eukaryotes, has been used most extensively and has shown great promise (46±49).
Cys 2 His 2 zinc ®nger proteins are attractive as a framework for novel DNA-binding proteins because of their relatively simple and modular structure. Besides the modularity provided by the separation of DBD and other functional domains, Cys 2 His 2 zinc ®nger proteins also show modularity in their DBDs. The DBDs of Cys 2 His 2 zinc ®nger proteins consist of several distinct Cys 2 His 2 zinc ®nger motifs that function relatively independently from each other. Each of these motifs (Fig. 5 ) has a bba structure and consists of a certain consensus sequence, namely X 2 -C-X 2,4 -C-X 12 -H-X 3,4,5 -H (where X can be any amino acid residue) (47) . Its structure is stabilized by hydrophobic interactions and by coordination of a zinc ion by the two cysteine and two histidine residues. Cys 2 His 2 zinc ®nger motifs typically function by binding DNAÐthrough presentation of their a helix in the major grooveÐat a 3-bp sub-site. They are commonly arranged as a covalent tandem of two, three or more separate motifs, together comprising the DBD of a TF (46±49).
The principles of Cys 2 His 2 zinc ®nger DNA recognition have been elucidated to quite an extent. Based mainly on research on the DBD of a certain natural 3-®nger protein, Zif268, it is believed that Cys 2 His 2 class zinc ®nger proteins primarily bind to one strand of the DNA double helix, and that they do so predominantly via positions ±1, 3 and 6 of the a-helix of each of its zinc ®nger motifs ( Fig. 5) (47, 49, 50) . These a-helix amino acid positions would, respectively, contact the 3¢-, middle and 5¢-nucleotides of the 3-bp subsite. Interestingly, these amino acids often showed striking conservations for recognition of the same nucleotides in different target sequences. However, attempts to extract from these conservations universal coding rules that relate zinc ®nger protein sequences and DNA binding site preferences have met with limited success (51±53). The lack of a simple recognition code of one amino acid to one nucleotide is thought to be due to the fact that apart from the primary contact residues (i.e. amino acids at positions ±1, 3 and 6 in the zinc ®nger a-helix)¯anking amino acids also play important roles in base speci®city (46±49). In this regard, it has been found that the individual ®ngers of a zinc ®nger protein, rather than interacting with consecutive 3-bp DNA targets, actually recognize 1 bp overlapping 4-bp DNA targets (54) . In this scheme, an additional fourth baseÐwhich is in the antisense strand relative to the ®rst three recognized basesÐis recognized by amino acid residue 2 of the zinc ®nger a-helix. Taking into account this fourth critical amino acid residue (at position 2 of the a-helix), a recent attempt to formulate a simple DNA recognition code for Cys 2 His 2 zinc ®nger binding was relatively successful (55) .
As it has proven dif®cult to devise universal coding rules for high af®nity DNA binding, engineering of sequence speci®-city of Cys 2 His 2 type zinc ®ngers has generally not been based on rational design alone, but has also relied on procedures that select for target DNA af®nity (46±49). Many of these selection procedures used phage display of randomized zinc ®ngers of the natural 3-®ngered protein Zif268 and have involved in vitro selection against target DNA sequences (50,56±59). Other procedures employed in vivo selection using yeast-based screening systems (60,61).
As mentioned above, each Cys 2 His 2 zinc ®nger motif of a polydactyl zinc ®nger protein binds to its sub-site relatively independently from its neighboring motifs. The so-called parallel' selection strategy is based on the assumption that this functional independence is absolute. Ideally it is then possible to separately select a zinc ®nger for each individual sub-site and subsequently make combinations of these ®ngersÐin any desired orderÐto design new polydactyl proteins (49) . Thus, if for each of the 64 possible DNA triplet sub-sites a speci®c zinc ®nger motif were pre-selected, it would be possible to target any DNA sequence just by stitching together combinations of these prede®ned zinc ®nger motifs (51, 57, 58) . The group of Barbas III, using phage display selection and optimization through systematic sitedirected mutagenesis, was able to develop zinc ®nger motifs speci®c for the 5¢-GNN-3¢ and 5¢-ANN-3¢ families of DNA triplets, which constitute half of all possible DNA triplet subsites (49, 57, 58, 62) . Although not every DNA sequence can be targeted by polydactyl proteins assembled from these motifs, it is believed that enough suitable, genome-speci®c target sites will exist in a given promoter region of interest (49) .
Making polydactyl zinc ®nger proteins using the parallel selection strategy has the advantage that once the zinc ®nger motifs are selected and optimized, new proteins can easily be constructed, from pre-de®ned motifs, using standard PCR methods. Ideally, no further design or selection will then be required. However, in practice, functional independence of neighboring zinc ®nger motifs is not absolute and, therefore, some cases require further optimization of the selected motifs (46±49).
The Pabo group addressed concerns of functional dependence of neighboring ®ngers by developing a`sequential' selection strategy (59) . In this strategy, the individual ®ngers are sequentially selected in the context of their neighboring ®ngers, thereby preventing potential problems that could be caused by target site overlap. Since any desired sequence can be targeted, this strategy seems especially useful in those cases where there is no¯exibility in target choice. A disadvantage of sequential selection is, however, that it requires the generation of and selection from multiple zinc ®nger libraries for each new polydactyl protein to be made (46±49,59).
A selection method that combines some of the advantages of the parallel and sequential approach has been developed more recently (50) . This`bipartite' strategy makes use of two pre-generated libraries, in each of which one-and-a-half ®ngers of a three ®nger protein are partially (affecting only the key residues of sequence recognition) randomized. In one library the N-terminal part of the protein is randomized and in the other the C-terminal. Selection from these two libraries is carried out in parallel against the two halves (respectively the 3¢-end and the 5¢-end half) of the target sequence of interest. After phage display, the selections of the two libraries are recombined and ®nal selections are performed against the full target sequence to obtain the optimal recombinant protein.
Like the sequential selection strategy, the bipartite system addresses the concerns of target-site overlap and also has the potential to target any desired sequence. The advantage over sequential selection is that, due to the use of pre-generated libraries, construction time would be shortened drastically. For the construction of each new polydactyl protein, the bipartite approach requires, however, multiple rounds of phage display selection, which in case of the parallel selection strategy, with its pre-de®ned ®nger motifs, is not necessary (47±50).
Each of the above-mentioned engineering strategies generated 3-®ngered zinc ®nger proteins that were targeted to sites of 9±10 bp. However, proteins targeted to extended sites (of 16±18 bp) should have increased af®nity for their targets and would potentially be genome-speci®c. Therefore, it has been attempted to generate longer proteins by covalently stitching together more than three ®ngers using canonical linkers, i.e. the short linkers by which the ®ngers in natural 3-®ngered proteins (like Zif268) are linked (Fig. 6A) . However, the resulting 6-or 9-®ngered proteins exhibited relatively low increases in binding af®nity, as compared to their 3-®ngered constituents (63) . It is assumed that these results are due to the proteins with more than 3 ®ngers linked canonically being too rigid and thus having to force too much unfolding of the DNA duplex.
In recognition of the dif®culties encountered with canonical linkers, there have been several other approaches of covalently linking together zinc ®nger units using non-canonical linkers (Fig. 6) . In one study, two 3-®nger units were linked bȳ exible linkers that were four or seven residues longer (respectively spanning gaps of up to 1 and 2 bp) than canonical linkers. The resulting 6-®ngered proteins showed more than 6000-fold tighter binding than the 3-®ngered constituent parts (64) . Other studies with multi-®ngered proteins containinḡ exible linkers also showed tighter binding, but of another magnitude, namely 100-to 500-fold (46) . Another approach for the covalent linkage of zinc ®nger units employed structured linkers. TFIIIA ®nger 4 and a non-sequencespeci®c zinc ®nger have been used to link two 3-®nger units (65) . These structured linkers were shown to be capable of spanning up to 10 bp of non-bound DNA and generally resulted in the binding of target sequences with more speci®city and af®nity as compared to the use of long¯exible linkers. Yet another approach of covalent linking involves slightly longer-than-canonical linkers which have been used to make 6-®nger proteins by linking three 2-®ngered units together (66) . Interestingly, these`3 Q 2' 6-®ngered proteins were shown to be more speci®c for their targets then their 2 Q 3' 6-®nger counterparts.
Non-covalent linkage of 2-or 3-®ngered units also provides a means to extend DNA target sites. Zinc ®nger units can be linked by dimerization if fused to dimerization domains (Fig. 6E) . In this regard, homodimerization of 2-®ngered proteins has been mediated by genetic fusion to Gal4 dimerization domains (67) . In another study, homo-dimerization of 2-®ngered proteins was mediated by peptides that had evolved in vitro from random sequences (68) . In a third study, homo-and heterodimerization of 2-®ngered proteins was accomplished by the leucine zippers of fos and jun (69) .
GENE MODIFICATION
In the previous sections, several types of designer molecules with engineered sequence speci®cities were described. These designer molecules differ in DNA-binding mechanisms and other properties, and consequently have different potencies for different types of gene modulation applications. By linking activators or repressors to the designer molecules, the expression of target genes can be arti®cially induced or repressed, as discussedÐalong with other strategiesÐin the next section, which deals with non-covalent transcription modulation. The present section will explore the potential of designer DNA binding molecules as modulators of endogenous gene function through stable gene modi®cation.
A challenging gene therapy direction is the induction of stable, site-speci®c gene modi®cations. In respective disease contexts, it could be advantageous to either inactivate or correct a certain endogenous gene. Sequence-speci®c designer molecules can potentially contribute in bringing about such gene modi®cations. Two mechanisms by which designer molecules have been shown to contribute to covalent gene modi®cation are (i) targeted mutagenesis, and (ii) targeted stimulation of homologous recombination and thereby stimulation of gene repair. The status of the research on stable gene modi®cation will be described for each of the designer molecule types.
Gene modi®cation by triplex-forming molecules
There have been various strategies for triplex-directed DNA damage. These have included those where TFOs are covalently linked to DNA-reactive agents (70±80). The rationale of these strategies is that the sequence-speci®c TFO conjugate mediates co-localization of the tethered mutagenic agent with the site targeted for mutagenesis. However, besides mutagen±TFO conjugates, TFO molecules alone have also been demonstrated to increase mutagenesis (74, 75, 81, 82) .
Several types of DNA reactive agents that have been conjugated to TFOs for the purpose of directed mutagenesis are photoinducable crosslinkers (70±76), radioactive agents (77), alkylating groups (78, 79) and certain molecules that can recruit DNA-damaging cellular enzymes (80) . Psoralen is a photoinducible crosslinker and is the most extensively studied mutagenic agent that has been conjugated to TFOs (70±76). When this mutagen is subjected to UV-A irradiation, it becomes cross-linked to the DNA which results in mutations. Psoralen±TFO conjugates have mediated gene mutagenesis at targeted sites on extrachromosomal reporter plasmids, both in vitro and in vivo (70±72), and on chromosomal sequences in mammalian cells (73±76). In a recent study, a TFO conjugated to a radioactive agent ( 125 I) was used to produce sequencespeci®c breaks within the human multidrug resistance (mdr1) gene of cultured cells (77) . Another recent study made use of TFOs conjugatedÐat both the 5¢ and 3¢ endsÐto an alkylating agent (phenylacetate mustard) (78) . Using a reporter plasmid with a preformed triple helix, this bis-conjugate was able to suppress HER-2/neu promoter activity by 60±70% in cancer cells. Usage of a different type of alkylating agent, 2-amino-6-vinylpurine, was also reported recently (79) . It was shown that in vitro formed triplexes between TFOs bearing this new nucleoside derivative and a reporter plasmid were able to deliverÐduring passage of the TFO treated plasmid in repairde®cient human cellsÐsite-speci®c modi®cations to a supF reporter gene. Yet another approach for triplex-mediated gene mutagenesis is the recruitment, by modi®ed TFOs, of cellular enzymes capable of in¯icting DNA damage. Recruiters that have been used for this purpose are camptothecin and rebeccamycin, both of which function by recruiting the cellular enzyme topoisomerase I. The feasibility of these procedures was shown in vitro (80) .
Interestingly, TFOs that are not conjugated to any mutagen are also capable of directing mutagenesis, albeit to a lesser extent than psoralen-TFOs (74, 75, 81, 82) . It has been suggested that this mutagenicity of unconjugated TFOs is due to provocationÐby the triplex structures aloneÐof certain DNA-repair pathways that are not error-proof in their DNA processing (81) . An early study that had capitalized on this intrinsic mutagenicity of TFOs was the ®rst work that provided evidence of ef®cacy of targeted mutagenesis of genomic sequences in live animals (82) . In this study systemic administration of TFOs to transgenic mice containing a chromosomal cognate triplex target site resulted in a 5-fold enhancement of mutation frequency at that site. Although the observed ef®ciency was relatively low, this study showed that triplex-mediated mutagenesis holds some promise in in vivo contexts.
Another mechanism by which TFOs have been shown to stably modify genes is the induction of homologous recombination and thereby the stimulation of gene repair. Strategies that aim to repair genes through homologous recombination are generally limited to the low frequency of homologous events in mammalian cells (83) . DNA damage, especially when including double-strand breaks, was shown to enhance the frequency of homologous recombination (84±86). As TFOs have the capability to direct site-speci®c DNA damage (see above), they are potential tools that can enhance homologous recombination (and thereby gene repair).
The feasibility of TFOs as inducers of recombination was shown both with psoralen conjugated (87±89) and nonconjugated TFOs (90±93). In some of these studies, certain bi-functional molecules were used, namely TFOs that were linked to a short recombination donor DNA fragment (90, 93) . In this approach the TFO would, besides sensitizing a target site to recombination, also function to direct the homologous donor to that site. Other studies provoked homologous recombination between direct repeats located on either extra-or intrachromosomal reporter constructs. An example of the latter is a study that was able to induce intrachromosomal recombination in mouse cells through intracellular production of ssDNA triplex-forming molecules (93) .
Gene modi®cation by synthetic polyamides
In contrast to triplex-forming molecules, synthetic polyamides have not been shown to exert DNA modifying effects by themselves. However, analogous to triplex-forming molecules, polyamides can be coupled to mutagenic agents and, thereby, have applicability for directed mutagenesis and, potentially, for stimulation of gene repair by homologous recombination. Until now, there have only been a few demonstrations of mutagenic polyamide-conjugates (94±96). In these reports, polyamides that were conjugated to DNA alkylating moieties cyclopropylpyrroloindole (95) and chlorambucil (94) were able to damage and crosslink SV40 DNA, predominantly at their designated 6±7-bp target sites. Furthermore, these polyamide conjugates exhibited inhibiting effects on cell cycling and cell growth. Of signi®cance, the chlorambucil-polyamide compound was found to be more potent in this respect than its parent compound chlorambucil, which is routinely used as an anti-tumor drug. Although the above studies demonstrate the feasibility of polyamideconjugate mediated mutagenesis, it remains to be established whether these types of compounds are capable of directing mutagenesis to speci®c target genes. In accordance, stimulation of homologous recombination by targeted mutagenesis has also not been demonstrated yet.
Gene modi®cation by designer zinc ®nger proteins
In principle, designer zinc ®nger proteins are capable of gene modi®cation by the same two mechanisms as TFOs, namely by directing mutagenesis to speci®c sites, and based on this, by increasing the occurrence of recombination events at speci®c sites. Several studies showed that both these mechanisms of gene modi®cation could be mediated by certain designer zinc ®nger proteins that were composed of a zinc ®nger DNA binding unit genetically fused to the non-speci®c cleavage domains of FokI (97±104). These`chimeric nucleases', which have been reviewed by Chandrasegaran and Smith (105) , can deliver site-speci®c double strand breaks (DSBs) to DNA and, as DSBs cause localized increases in recombination rates, have potential as stimulators of gene targeting. Two recent back-to-back publications in Science described enhanced gene targeting with chimeric nucleases (102, 104) . One study showed stimulated targeting of an integrated GFP reporter construct in human 293 cells (104) , while the other demonstrated increased targeting of the yellow gene on the X chromosome in Drosophila (102).
REGULATION OF GENE TRANSCRIPTION
A promising application for designer DNA-binding agents is the therapeutic modulation of endogenous genes at the root of their function, namely at the level of transcription. In various disease contexts, it would be very bene®cial to have the capability of transiently turning on or off speci®c endogenous genes. Therefore, tools capable of gene-speci®c modulation of endogenous gene transcription could be of great therapeutic value. The different designer DNA-binding agents described in this studyÐTFOs, polyamides, designer zinc ®nger proteinsÐall have potential as such tools. Here their applicability as modulators of gene transcription will be explored.
There are several general mechanisms that designer DNAbinding agents have employed to modulate gene transcription (Fig. 7) . These mechanisms of transcription regulation include (i) blocking of transcription elongation by targeting a site within the transcribed region of the gene (Fig. 7A) , (ii-a) blocking or (ii-b) promoting transcription initiation by targeting a site within the regulatory region of a gene (Fig. 7B) , and (iii-a) repression or (iii-b) activation of gene transcription by fusion of an appropriate trans-effector domain to the DNAbinding agent (Fig. 7C) . In this section, it will be investigated to what extent the different designer molecules have employed these distinct modes of transcription modulation.
Regulation of gene transcription by triplex-forming molecules
The ®rst reported case of triplex-mediated modulation of transcription employed blocking of transcription initiation (mechanism ii-a). In this mechanism, the DNA-binding agent interferes with the binding of transcriptional activators or with the formation of the transcription initiation complex. In that particular study, triplex formation was targeted to the regulatory region of the c-myc gene and this resulted in inhibition of transcription in vitro (106). Since then, there have been more studies that demonstrate inhibition of transcription by TFOs targeted to regulatory sequences of genes. These studies were performed either in vitro or in vivo, on extrachromosomal (107±112), but also on endogenous targets. Modulation of expression of endogenous gene targets has been successful for a broad range of genes including c-myc (113, 114) , interleukin-2 receptor (115), aldehyde dehydrogenase (116), GM-CSF (117), HER2/neu (118), monocyte chemoattractant protein-1 (MCP-1) (119) and Ets2 (120) .
In addition to transcription inhibition, triplex formation targeted to the regulatory region of a gene could potentially result in transcription activation (mechanism ii-b). This is the case when the triplex would interfere with the binding of a transcriptional repressor. This principle was shown in a study where a TFOÐdesigned to speci®cally bind at a repressor binding siteÐwas able to up-regulate murine immunoglobulin heavy chain transcription in B cell culture lines (121) .
Targeting triplex formation to sites within the transcribed sequence of a gene may inhibit transcription by bringing RNA polymerase to a halt, that is by blocking transcription elongation (mechanism i). This mechanism has been demonstrated, both with (extrachromosomal) reporter constructs (122±124) and with endogenous genes (125±127). In general, it has been found that blocking of elongation with DNA oligonucleotides that have natural (unmodi®ed) phosphodiester backbones is hard to accomplish, probably due to the requirement that triplex stability must be suf®ciently high to physically arrest the RNA polymerase. Accordingly, most studies that block transcription elongation by TFO binding do so by covalent crosslinking of the TFO and duplex DNA. However, several studies that use N3¢-P5¢ phosphoramidate linkages instead of the normal phosphodiester backbone report inhibition of transcription elongation by non-covalent triplexes, both in vitro (17, 128) and in vivo (129, 130) . Endogenous genes that have been down-regulated by triplex-mediated inhibition of transcription elongation have included insulin-like growth factor-1 (IGF-1) (125), IGF-1 receptor (IGF-1R) (126) , tumor necrosis factor (127), ICAM-1 (131), and survivin (132). In the above-mentioned studies targeting IGF-1 and IGF-1R genes, the triplex-forming molecules consisted of RNAs that were generated intracellularly. In these experiments, cells that constitutively expressed triplex-forming RNAs showed down-regulation of the respective genes.
By fusing transcriptional activator domains to designer DNA-binding molecules, they can serve as arti®cial transcription activators (mechanism iii-b). These arti®cial transcription activators would function, analogous to natural transcription activators, by recruiting the transcriptional machinery to a promoter near the transcription factor binding site. There has been one report demonstrating this mechanism for TFOs (133) . A TFO conjugated to VP16, which is a 16 amino acid peptide transcriptional activator, was able to increase transcription from a plasmid construct.
Another mechanism to achieve triplex-mediated activation of transcription involves the unique way of triplex formation by bis-PNAs, which are molecules that consist of two PNA strands covalently linked together (30) . Triplex formation by bis-PNA molecules involves invasion of the DNA duplex and displacement of the oligopyrimidine DNA strand. One PNA strand replaces the displaced DNA strand by base-pairing with the oligopurine target strand, while the second PNA strand is folded back to the consequent PNA:DNA duplex to form a PNA*PNA:DNA triplex. This structure, with its single stranded DNA loop resembling a transcription bubble, has been shown to function as an arti®cial promoter in vitro and in mammalian cells (134, 135) .
Regulation of gene transcription by synthetic polyamides
Employment of synthetic polyamides as transcription modulators is a relatively new ®eld of research. However, several studies have already reported on polyamide mediated regulation of gene transcription in cellular contexts. In this regard, two studies demonstrated that polyamides targeted to regulatory sequences of genes were able to inhibit gene transcription through mechanism ii-a, that is blocking of transcription initiation. First of all, hairpin polyamides targeted within the binding site of transcription factor TFIIIA inhibited RNA polymerase III mediated transcription of the 5S RNA genes, in vitro and in cultured Xenopus kidney cells (136) . In another study, hairpin polyamides were targeted at transcription factor binding sites within the HIV-I enhancer/ promoter region (137) . This gave inhibition of HIV-I transcription in a cell free assay andÐwhen using two polyamides targeted at different transcription factor binding sitesÐto 99% inhibition of virus replication in cells. Another interesting example of blocking of transcription initiationÐin cell free experiments, howeverÐconcerns polyamides designed for targeting HPV-encoded E2 (a transcription and replication factor) DNA binding sites in the HPV genome (138) . This study demonstrated that a tandem hairpin polyamide indirectly inhibited binding of E2 to its DNA target sites according to a model in which these target sites are prevented from acquiring their intrinsic bend necessary for E2 protein binding.
Targeting of synthetic polyamides to transcription regulatory regions has not only been pursued for the purpose of blocking, but also for promotion of transcription initiation (mechanism ii-b). This is exempli®ed by a study by Coull et al. in which a HIV-LTR targeted polyamide speci®cally blocked binding of a certain host factor, LSF, resulting in de-repression of the LTR (139) . Importantly, the increased LTR expression was observed using integrated reporter constructs in cultured cells.
Polyamides have also been used for the activation of transcription by conjugation to transcriptional activator domains (mechanism iii-b). A hairpin polyamide was linked to the 20 amino acid peptide activation domain AH (140). This 4.2 kDa molecule was able to up-regulate transcription in a cell free system. A related study attempted to make a synthetic polyamide transcriptional activator of minimal size (141) . A hairpin polyamide was linked to the 16 amino acid peptide activation domain VP16. This molecule, with a total size of 3.2 kDa, was also capable of up-regulating transcription in a cell free system. More recently, Arora et al. linked transcriptional activators to DNA binding polyamides using rigid poly-L-proline linkers (142) . Again in cell-free experiments, they found that an optimal linker length (36± 45 A Ê ) exists for transcriptional activation by their polyamide conjugates.
Despite some successes in cultured cells, it remains dif®cult to echo the results of cell free assays in experiments using cells (143) . It has been suggested that this dif®culty of intracellular use of polyamides could be due to inef®cient polyamide travel to the nucleus (35, 144) . However, with respect to the intracellular biological activity of polyamides, Laemmli's group showed signi®cant in vivo results using polyamides targeted to satellite regions of Drosophila chromosomes (145) . When fed to Drosophila, these polyamides were able to induce altered gene expression by modifying chromatin structure.
Regulation of gene transcription by designer zinc ®nger proteins
An early case of designer zinc ®nger protein-mediated modulation of gene transcription employed a 3-®nger protein that was targeted to a site deep within the transcribed region of an integrated reporter construct (51) . This molecule inhibited transcription from the reporter construct, by blocking transcription elongation (mechanism i). Several other attempts to inhibit transcription by targeting within the transcribed region of a gene showed no apparent inhibition (146±148). Therefore, it is now generally believed that zinc ®nger proteins are not very well suited for this particular mechanism of transcription modulation (49) .
Interfering with natural transcription factor binding is probably less challenging than placing a steric blockade in the path of RNA polymerase. Therefore, it is conceivable that designer zinc ®nger proteins will hold more promise for modulating transcription initiation (mechanism ii) than that they were shown to hold for blocking transcription elongation (mechanism i). Indeed, several studies reported that zinc ®nger proteins targeted within the regulatory sequences of genes were able to block transcription initiation (61, 64, 146, 148, 149) . These studies used either transiently transfected or integrated reporter constructs.
The most promising applications of designer zinc ®nger proteins are probably those that mimic the functional modularity of natural transcription factors. By genetically fusing engineered zinc ®nger DBDs to natural non-speci®c transcriptional EDs, it becomes possible to make new, arti®cial transcription factors. Several different transcriptional effector domains have been reported to be fused to designed zinc ®nger DBDs. These effector domains have included the activation domains VP16 (150) and p65 (151) , and the repression domains KRAB (152), SID (153) and v-ErbA (154) . Designer zinc ®nger units fused to the appropriate effector domains allow for both activation and repression of target gene transcription.
Several endogenous genes have already been modulated by these arti®cial zinc ®nger transcription factors. The ®rst study to report on the regulation of an endogenous chromosomal gene employed a 5-®ngered protein fused to two KRAB domains, to down-regulate the MDR1 multidrug resistance gene (61) . Two other studies reported on 6-®ngered zinc ®nger proteins fused to either KRAB or VP64 (a tetramer of VP16) effector domains, that were able to down-or up-regulate the ErbB-2 and ErbB-3 genes (62, 155) . Furthermore, a 3-®nger protein fused to VP16 was able to activate erythropoietin gene transcription (156) . VEGF-A gene transcription was shown to be activated by 3-®ngered proteins fused to either VP16 or p65 (157) . More recently, the nuclear hormone receptor PPARg was effectively knocked down by a 6-®nger protein fused to KRAB (158) . Also recently, a 5-®ngered zinc ®nger protein fused to VP16 was reported to induce bax expression (159) . Furthermore, in another recent study, 3-®ngered zinc ®nger proteins were able to speci®cally modulate the transcription of IGF2 and H19 genes (160) . This time, transcriptional activation was performed by protein fusions containing either VP16 or p65, while repression was accomplished using the v-ErbA transcriptional repressor protein. Of signi®-cance, these designer transcription factors were able to reactivate transcriptionally silent alleles of the IGF2 and H19 genes, thus demonstrating that regulation of imprinted genes is feasible.
Recently, the therapeutic potency of arti®cial zinc ®nger transcription factors was demonstrated for the ®rst time in a living animal model (161) . After administration into two different mouse models, arti®cial transcription factors consisting of VP16 fused to DBDs [containing either 3 (157) or 6 (161) zinc ®ngers] that were targeted to regulatory sequences of VEGF-A were shown to induce angiogenesis in mouse ears and to accelerate wound healing.
DISCUSSION

Engineering of sequence speci®city
Overall, all three different DNA binding modalities described in this review have proven to be suitable as frameworks for the engineering of novel sequence speci®city. All three exhibit a degree of modularity in their DNA-recognition mechanisms down to the level of single nucleotide base or base-pair contacts. It is essentially this modularity that yields the amenability of these agents to manipulation of sequence speci®city.
For gene modulation purposes, it would be very useful if a given type of designer molecule could be targeted to any desired sequence, so that there would be no limitation in target site choice. In this regard, TFOs have a major limitation as their DNA-recognition code is restricted to recognition of purine-rich target strands. Despite promising attempts to expand the TFO DNA-recognition code by usage of novel, synthetic base analogs, the requirement remains for the greater part of the target strand to consist of purines. In contrast, polyamides have been successfully developed to recognize all four Watson±Crick base pairs and therefore can potentially address any DNA target site. However, it is not conceivable that all possible sites would actually be bound with the necessary af®nity and suf®cient speci®city. Based on already characterized polyamides, it has been estimated that the present generation of polyamides can targetÐwith suf®cient af®nity and speci®cityÐas much as 50% of the potential target DNA sites in any promoter (35) . Compared to TFOs and polyamides, designer Cys 2 His 2 zinc ®nger proteins probably exhibit the most¯exibility in target site choice. It is thought that virtually any sequence can be targeted by zinc ®nger proteins since their generation can make use of high af®nity selection against DNA targets. However, selection procedures are laborious and therefore, in practice, zinc ®nger proteins with novel speci®cities are often made by assembly from available repertoires of zinc ®nger domains with pre-de®ned speci®city. Although somewhat limiting target site choice, this assembly process has proven feasible, as many of the designer zinc ®nger proteins discussed in this review were constructed this way.
In vivo delivery and functionality
With the ultimate goal of in vivo modulation of endogenous genes in human patients, various related issues like delivery, cellular uptake, nuclear transport and target DNA accessibility must be addressed for each of the different types of designer DNA-binding molecules. In relation to each of these issues, the different types of agents have very diverse characteristics and will therefore have distinct requirements and promises for their employment as gene modulators.
As TFOs are anionic molecules, and, compared to the synthetic polyamides, have a relatively high molecular weight (35) , they suffer from poor cellular uptake when administered directly (7, 35) . In contrast, polyamides, which are uncharged and relatively small, are mostly quite cell-permeable. Strategies to improve direct delivery of TFOs to cells have included cationic lipids (118, 162) , DNA condensing agents (163) , cell permeabilization agents (88, 117, 164) and coupling of the TFO to hydrophobic residues like cholesterol (165) . Furthermore, indirect delivery of TFOs, i.e. intracellular production of TFOs by expression vectors, might also provide means to achieve more ef®cient delivery to cells, especially in in vivo contexts. In this regard, systems for the intracellular production of RNA (166) and of ssDNA (167) have been developed.
Regarding cellular uptake, designer zinc ®nger proteins could, in theory, be delivered to cells directly as a protein.
However, the different studies reporting on endogenous gene regulation by designer zinc ®nger proteins (that were described in this study) all delivered these proteins into cells as a transgene. Vectors that have been used for the purpose of introducing zinc ®nger protein encoding genes to cells have included plasmids, retroviruses and adenoviruses.
In order to reach their DNA targets, designer DNA-binding molecules must, besides penetrating the cellular membrane, be transported to the nucleus. In this regard, it is hypothesized by Sedelnikova et al. that TFOs, upon delivery into cells, become trapped by unknown binding factors that keep TFOs from ®nding their gene targets (77) . Interestingly, TFOs would ef®ciently be transported into the nucleus by these factors, but would remain bound to them there. This is in contrast to TFOs that were conjugated to the nuclear localization signal (NLS) peptide of SV40 large T antigene (77) . These, and other NLS conjugates, are believed to be delivered into the nucleus (by the nuclear pore transport system) and, upon delivery, released by the transport protein, thereby being potentially available to interact with their DNA targets (77, 168) . In this regard, most designer zinc ®nger proteins have been genetically fused to NLSs, and therefore also travel to the nucleus via NLS-mediated mechanisms.
The ®eld of DNA-binding polyamides has encountered dif®culties with intracellular transport. Although cell-permeable and considerably smaller than some proteins capable of crossing through the nuclear pores (169), polyamides do not appear to travel to the nucleus ef®ciently. In a variety of cell types polyamides were found to accumulate mainly in the cytoplasm (or cytoplasmic vesicles), not in the nucleus (38, 144, 170) . The group of Dervan has addressed these poorly understood mechanisms of polyamide cellular entry and localization in order to re-engineer polyamides with speci®c nuclear uptake properties (38, 144) . In this regard, recent studies have introduced new side-by-side amino acid pairs (benzimidazole/imidazole, imidazopyridine/pyrrole and hydroxybenzimidazole/pyrrole) that can participate in DNA minor groove recognition by synthetic polyamides (171, 172) . It is thought that novel polyamide classes harboring new types of amino-acid pairs may possess altered, potentially useful properties with respect to cell permeation, cellular distribution and degradation.
Once designer DNA-binding agents are delivered to the nucleus and are available for interaction with their DNA targets, the question remains whether these targets are suf®ciently accessible for binding within their chromosomal contexts. In this regard, a general approach, to ensure that inaccessibility due to chromatin structure is not an issue, is to target within DNase-I hypersensitive regions, as was done in a study using designer zinc ®nger proteins (157) . As outlined below, several studies have addressed the important issues of target accessibility and in vivo functionality.
In case of TFOs, Macris and Glazer recently showed that induction of transcriptional activity at a chromosomal target site in mammalian cells resulted in increased TFO binding (173) . Their results also showed strong RNA polymerase activity-dependence of this observed enhancement of chromosomal TFO targeting, indicating that the active transcription through a triplex target region is especially favorable for triplex formation. Related to this, Majumdar et al. recently reported that the biology of the cell, speci®cally the cell cycle status, affects the ef®ciency of TFO targeting (174) . They demonstrated that psoralen-linked TFOs exhibited greatest mutagenic activity in S phase cells.
Polyamides exhibit unique capabilities with respect to target DNA accessibility in the context of chromatin structure. Of importance, polyamides have been shown to be capable of binding ef®ciently to nucleosomal DNA, even if their DNA targets are partially facing the histone octamer (175) . Related to this, polyamides that bind targets within nucleosomal DNA were shown to be able to in¯uence nucleosome translocation (176, 177) . Thus polyamides display potential for the regulation of endogenous genes by unique mechanisms. In fact, the in vivo feasibility of altering gene expression through modi®cation of chromatin structure using sequence-speci®c polyamides had already been shown earlier by Laemmli and co-workers (145) .
Concerning designer zinc ®nger proteins, two studies that address the issue of their in vivo functionality were published recently (178, 179) . First, Bae et al. isolated zinc ®nger domains from the human genome and tested their sequencespeci®cities using a reporter gene expression assay in yeast (178) . The subsequent usage of these characterized human zinc ®ngers as modular building blocks for the derivation of novel sequence-speci®c DNA-binding proteins resultedÐ upon fusion with appropriate effector domainsÐin the generation of potent modulators of gene transcription. It is proposed by Bae et al. that these naturally occurring human zinc ®ngers, when compared with engineered zinc ®ngers, have favorable DNA-binding properties in vivo and, furthermore, may be preferable in therapeutic settings as they are less likely to provoke host immune responses. Another intriguing approach that selects for in vivo functionality and which exempli®es the¯exibility of Cys 2 His 2 zinc ®nger engineering came from Blancafort et al. (179) . They made repertoires of arti®cial transcriptional activators that contained DBDs consisting of randomized combinations of pre-characterized zinc ®ngers. These libraries were delivered to cells by a retroviral vector, after which infected cells were selected (by FACS) for the over-expression of certain surface proteins of interest. Several of the individual zinc ®nger regions that were recovered from selected cells (by PCR) were con®rmed to be able to up-or down regulate (by fusion to the appropriate effector) the relevant proteins. Thus, this report demonstrated the feasibility of directly selecting zinc ®ngers for their in vivo functionality. permanent and speci®c inactivation or correction of those genes is clearly a very rational and elegant concept. TFOs and designer ZFPs should hold promise in this ®eld of gene modulation as they both have been shown to be able to deliver site-speci®c damage to genes, as reviewed in this study. Such TFO-or designer ZFP-delivered damage to DNA has utility as it could achieve inactivation of the targeted gene or, quite the opposite, repair of the gene concerned by serving to attract corrective homologous recombination upon co-delivery of recombination donor (gene targeting). Until now, however, targeting ratios for TFO-or designer ZFP-mediated mutagenesis and recombination have been low. Therefore, most utility of the different gene modi®cation technologies probably lies in ex vivo approaches that can select for modi®ed cells, or in the treatment of those types of diseases that do not require the majority of cells to be corrected. Furthermore, there could also be promise for certain diseases in which corrected cells would have an acquired growth advantage.
SEQUENCE-SPECIFIC MODULATION OF ENDOGENOUS GENE FUNCTION: CONCLUSIONS AND PROSPECTS
Modulation
Modulation of endogenous gene function through regulation of gene transcription is another important and appealing gene therapy endpoint for which designer DNA-binding molecules would have great utility. Each of the types of designer DNA-binding molecules described in this study has potential as a sequence-speci®c transcriptional modulator of endogenous genes. TFOs have been shown to inhibit several endogenous genes by blocking the initiation or the elongation of transcription, respectively, by interfering with transcription factor binding and arresting RNA polymerase. If delivery issues are addressed, TFOs probably have most promise as transcription inhibitors, as activation of transcription by TFOs would involve the risk of the intrinsic mutagenicity of TFOs. Polyamides have been shown to block the initiation of transcription of at least one endogenous gene (136) . The utility of polyamides might lie for a great part in their cellular uptake properties. It is conceivable that, in order not to compromise these properties, they will not be conjugated to too large effector domains. Therefore, if their nuclear transport dif®culties could be resolved, they would probably have good potential as transcription inhibitors (or possibly also as activators) by interfering with transcription factor binding. However, polyamides certainly also hold promise as smallmolecule transcription activators when conjugated to peptide effector domains of minimal size. Designer ZFPs show signi®cant potential as arti®cial transcription factors. Fused to transcriptional effector domains, they were shown to be potent transcriptional mediators of several endogenous genes. Moreover, it has recently been established that they can evoke therapeutically relevant levels of effects in mouse models (161) . Furthermore, they show the most versatility with respect to the usage of functional domains. Examples of potentially useful domains other than transcriptional effectors are domains with transporter function and ligand binding domains. Approaches fusing zinc ®nger DBDs with different types of ligand binding domains have already resulted in the construction of several types of small molecule inducible transcription factors (49,180±183) .
In conclusion, in the ®eld of therapeutic gene modulation, engineering of DNA-binding agents with designed sequence speci®city represents an exciting new approach. Modulation of endogenous genes has clear advantages over conventional gene therapy strategies. However, further research is warranted for this approach to show full potency, especially on expanding the target site choice and on the issues of delivery and DNA accessibility. Nonetheless, the different types of designer DNA-binding agents described here clearly have potential as powerful sequence-speci®c gene modulators, by exerting their effect either through stable gene modi®cation or through regulation of transcription.
